Dyne Therapeutics Inc. Company Profile
NASDAQ: DYNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Dyne Therapeutics at a glance
Dyne Therapeutics Inc. (NASDAQ: DYN) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Waltham, MA. Dyne Therapeutics is led by Mr. John G. Cox M.B.A. and employs about 289 people. The company's shares have traded publicly since 2020.
At a market capitalization of $2.98 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001818794, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Dyne Therapeutics do?
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Dyne Therapeutics Inc.
- Ticker
- NASDAQ: DYN
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. John G. Cox M.B.A.
- Employees
- 289
- Headquarters
- 1560 Trapelo Road, Waltham, MA, United States
- Phone
- 781 786 8230
- Website
- dyne-tx.com
- IPO year
- 2020
- Market cap
- $2.98B
- SEC CIK
- 0001818794
Companies similar to Dyne Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELVNEnliven Therapeutics Inc. | 41.36 | -2.43% | $3.03B | vs DYN |
| ARQTArcutis Biotherapeutics Inc. | 24.17 | +1.05% | $3.04B | vs DYN |
| RCUSArcus Biosciences Inc. | 24.52 | +0.99% | $3.08B | vs DYN |
| ZLABZai Lab Limited ADR | 25.31 | -1.06% | $2.84B | vs DYN |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.43 | -5.35% | $2.75B | vs DYN |
| PGENPrecigen Inc. | 7.54 | -0.13% | $2.70B | vs DYN |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs DYN |
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs DYN |